ONECUT2: A Validated Drug Target and Lineage Plasticity Driver in Prostate Cancer and Other Malignancies.

The CUT/Hox transcription factor ONECUT2 (OC2) promotes lineage plasticity and is a confirmed therapeutic target in prostate cancer and several other malignancies where cell phenotype plays a substantial role in treatment resistance. OC2 governs a broad growth and lineage identity process in prostate cancer that promotes neuroendocrine (NE) differentiation, androgen receptor (AR) suppression, and the emergence of a wide range of treatment-resistant pathways. The mode of action of OC2 includes incorporation of the protein into transcription complexes at gene promoters as an activator and repressor, alteration of chromatin accessibility and epigenetic marks, and extensive alteration of large-scale chromatin modifications, such as super-enhancers and chromatin loops. Notably, OC2 may be unique among NE drivers in that it can promote AR-indifference in adenocarcinoma as a direct upstream activator of the glucocorticoid receptor, thus assuming indirect control of a portion of the AR cistrome. OC2 expression and activity increase substantially following hormone therapy in association with aggressive disease in prostate and breast cancer. Experiments in model systems have shown that OC2 has a survival function in both human castration-sensitive and castration-resistant prostate cancer cells. OC2 can be targeted directly with a family of novel small molecule inhibitors that show therapeutic efficacy in vivo in prostate, breast and gastric cancer models, including regression of established distant metastases in mice. These findings suggest that inhibition of OC2 clinically may confer substantial therapeutic benefit in some aggressive malignancies, including in localized, hormone-sensitive disease.

• Publication year

  2025

• Venue

  Endocrine-Related Cancer

• Publication date

  2025-11-12

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1530/ERC-25-0272PMID 41222115
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ONECUT2 reprograms neuroendocrine fate and is an actionable therapeutic target in small cell lung cancer

  2025cited by this paper
• YTHDF2-mediated m6A modification of ONECUT2 promotes stemness and oxaliplatin resistance in gastric cancer through transcriptionally activating TFPI.

  2025cited by this paper
• Cancer statistics, 2025

  2025cited by this paper
• Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer

  2024cited by this paper
• Understanding the function of Pax5 in development of docetaxel-resistant neuroendocrine-like prostate cancers

  2024cited by this paper
• Increased ONECUT2 induced by Helicobacter pylori promotes gastric cancer cell stemness via an AKT-related pathway

  2024cited by this paper
• ONECUT2 acts as a lineage plasticity driver in adenocarcinoma as well as neuroendocrine variants of prostate cancer

  2024cited by this paper
• ONECUT2 is a druggable driver of luminal to basal breast cancer plasticity

  2024cited by this paper
• Targeted protein degradation: from mechanisms to clinic

  2024cited by this paper
• Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series

  2024cited by this paper
• Tumour response to hypoxia: understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours

  2024cited by this paper
• Neuronal miR-9 promotes HSV-1 epigenetic silencing and latency by repressing Oct-1 and Onecut family genes

  2024cited by this paper
• The homeodomain regulates stable DNA binding of prostate cancer target ONECUT2

  2024cited by this paper
• Concerted transcriptional regulation of the morphogenesis of hypothalamic neurons by ONECUT3

  2024cited by this paper
• Chromatin accessibility and pioneer factor FOXA1 restrict glucocorticoid receptor action in prostate cancer

  2023cited by this paper
• ONECUT2 regulates RANKL-dependent enterocyte and microfold cell differentiation in the small intestine; a multi-omics study

  2023cited by this paper
• Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.

  2023cited by this paper
• Multi-level functional genomics reveals molecular and cellular oncogenicity of patient-based 3′ untranslated region mutations

  2023cited by this paper
• Targeting the Androgen Signaling Axis in Prostate Cancer.

  2023cited by this paper
• Autonomous action and cooperativity between the ONECUT2 transcription factor and its 3′ untranslated region

  2023cited by this paper
• Epigenetics as a mediator of plasticity in cancer

  2023cited by this paper
• Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling

  2022cited by this paper
• Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets

  2022cited by this paper
• Activation of ONECUT2 by RB1 loss in castration-resistant prostate cancer.

  2022cited by this paper
• Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

  2022cited by this paper
• ONECUT2 which is targeted by hsa-miR-15a-5p enhances stemness maintenance of gastric cancer stem cells

  2021cited by this paper
• Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis.

  2021cited by this paper
• Resistance to second-generation androgen receptor antagonists in prostate cancer

  2021cited by this paper
• Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression

  2021cited by this paper
• Robust regulatory architecture of pan-neuronal gene expression

  2021cited by this paper
• Lineage plasticity in cancer: a shared pathway of therapeutic resistance

  2020cited by this paper
• Up-regulated ONECUT2 and down-regulated SST promote gastric cell migration, invasion, epithelial-mesenchymal transition and tumor growth in gastric cancer.

  2020cited by this paper
• Construction of ceRNA Coexpression Network and Screening of Molecular Targets in Colorectal Cancer

  2020cited by this paper
• ONECUT2 upregulation is associated with CpG hypomethylation at promoter‐proximal DNA in gastric cancer and triggers ACSL5

  2020cited by this paper
• Competitive endogenous RNA is an intrinsic component of EMT regulatory circuits and modulates EMT

  2019cited by this paper
• Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.

  2019cited by this paper
• ONECUT2 is a driver of neuroendocrine prostate cancer

  2019cited by this paper
• ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis

  2018cited by this paper
• Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.

  2018cited by this paper
• The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy

  2017cited by this paper
• Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome.

  2016cited by this paper
• Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer

  2016cited by this paper
• Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer

  2015cited by this paper
• The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer.

  2015cited by this paper
• Aggressive Variants of Castration-Resistant Prostate Cancer

  2014cited by this paper
• Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade.

  2013cited by this paper
• Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer

  2013cited by this paper
• ChIPBase: a database for decoding the transcriptional regulation of long non-coding RNA and microRNA genes from ChIP-Seq data

  2012cited by this paper
• Onecut-2 knockout mice fail to thrive during early postnatal period and have altered patterns of gene expression in small intestine.

  2010cited by this paper
• Expression patterns of PAX5, c-Met, and paxillin in neuroendocrine tumors of the lung.

  2010cited by this paper
• ChEA: transcription factor regulation inferred from integrating genome-wide ChIP-X experiments

  2010cited by this paper
• PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription

  2009cited by this paper
• Scanning copy number and gene expression on the 18q21‐qter chromosomal region by the systematic multiplex PCR and reverse transcription‐PCR methods

  2007cited by this paper
• Role of the Onecut transcription factors in pancreas morphogenesis and in pancreatic and enteric endocrine differentiation.

  2007cited by this paper
• Retrograde BMP signaling regulates trigeminal sensory neuron identities and the formation of precise face maps.

  2007cited by this paper
• Control of liver cell fate decision by a gradient of TGF beta signaling modulated by Onecut transcription factors.

  2005cited by this paper
• TRED: a Transcriptional Regulatory Element Database and a platform for in silico gene regulation studies

  2004cited by this paper
• OC-2, a Novel Mammalian Member of the ONECUT Class of Homeodomain Transcription Factors Whose Function in Liver Partially Overlaps with That of Hepatocyte Nuclear Factor-6*

  1999cited by this paper

• No citing papers are available for this paper.